RARA and acute promyelocytic leukemia: In support of our findings, Poplineau and colleagues recently found that in a genetically engineered mouse model (GEMM) of ATRA-resistant PLZF-RARα APL (arising from the variant t(11;17)(q23;q21) translocation), a structural analog of GSK-343 (GSK-126) was ineffective in preventing disease progression or inducing leukemic blast differentiation with or without ATRA (Poplineau et al., 2022).